Michael Berry - Enfusion Chief Officer
| ENFNDelisted Stock | USD 10.76 0.00 0.00% |
Insider
Michael Berry is Chief Officer of Enfusion
| Phone | 312 253 9800 |
| Web | https://www.enfusion.com |
Michael Berry Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Berry against Enfusion stock is an integral part of due diligence when investing in Enfusion. Michael Berry insider activity provides valuable insight into whether Enfusion is net buyers or sellers over its current business cycle. Note, Enfusion insiders must abide by specific rules, including filing SEC forms every time they buy or sell Enfusion'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Berry over two months ago Insider Trading | ||
Michael Berry over three months ago Disposition of 4608 shares by Michael Berry of NetApp at 123.32 subject to Rule 16b-3 | ||
Michael Berry over three months ago Disposition of 1437 shares by Michael Berry of NetApp subject to Rule 16b-3 | ||
Michael Berry over six months ago Disposition of 6396 shares by Michael Berry of NetApp at 121.22 subject to Rule 16b-3 |
Enfusion Management Efficiency
The company has return on total asset (ROA) of 0.0305 % which means that it generated a profit of $0.0305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0442 %, meaning that it created $0.0442 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities.Enfusion currently holds 20.31 M in liabilities. Enfusion has a current ratio of 8.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Enfusion's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Martin Simoncic | PROS Holdings | 42 | |
| Sherry Lautenbach | PROS Holdings | 49 | |
| Charles Longfield | Blackbaud | 67 | |
| Anthony Zingale | ON24 Inc | 63 | |
| Chinh Chu | E2open Parent Holdings | 53 | |
| Catherine Lesjak | PROS Holdings | 62 | |
| Srinivasagopalan Ramamurthy | Freshworks | 58 | |
| James Offerdahl | CS Disco LLC | 64 | |
| Colette Burnette | CS Disco LLC | 62 | |
| Pradeep Rathinam | Freshworks | 53 | |
| John Allessio | PROS Holdings | N/A | |
| Deep Shah | E2open Parent Holdings | N/A | |
| Thomas Masotto | ON24 Inc | N/A | |
| Irwin Federman | ON24 Inc | 84 | |
| Yael Zheng | Meridianlink | 56 | |
| A Rohde | Meridianlink | 39 | |
| Reema Poddar | Meridianlink | 51 | |
| J Rogers | E2open Parent Holdings | N/A | |
| William Magnuson | Braze Inc | 37 | |
| Scott Hill | CS Disco LLC | 57 | |
| Stacey Epstein | Freshworks | 55 | |
Management Performance
| Return On Equity | 0.0442 | |||
| Return On Asset | 0.0305 |
Enfusion Leadership Team
Elected by the shareholders, the Enfusion's board of directors comprises two types of representatives: Enfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enfusion. The board's role is to monitor Enfusion's management team and ensure that shareholders' interests are well served. Enfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Dorton, Chief Officer | ||
| Michael Berry, Chief Officer | ||
| Lorelei Skillman, Chief Officer | ||
| Vivek Ranka, Head Technology | ||
| Stephen Malherbe, Managing Partner | ||
| Oleg Movchan, Interim Director | ||
| Matthew Campobasso, General Secretary | ||
| Bronwen Bastone, Chief Officer | ||
| Joseph Defeo, Global Production | ||
| Lotte Tonsberg, Head EMEA | ||
| Kabir Kohli, MD Services | ||
| Jeff Young, Head Implementation | ||
| Iris Wang, Chief Officer | ||
| Brian Murphy, Investor | ||
| Matt Campobasso, General Counsel | ||
| Robert Taylor, Head Support | ||
| Ignatius Njoku, Head Relations | ||
| Bradley Herring, Chief Officer | ||
| Neal Pawar, Chief Officer | ||
| Daniel Groman, Chief Officer | ||
| Valeria Gutowski, Chief Officer |
Enfusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0442 | |||
| Return On Asset | 0.0305 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.03 % | |||
| Current Valuation | 1.01 B | |||
| Shares Outstanding | 94.8 M | |||
| Shares Owned By Insiders | 4.73 % | |||
| Shares Owned By Institutions | 96.25 % | |||
| Number Of Shares Shorted | 1.3 M | |||
| Price To Earning | 0.11 X |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Enfusion Stock
If you are still planning to invest in Enfusion check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enfusion's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |